Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 16/20 | 0.48 |
| ▸ | PPARA | Q07869 | 16/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038315 | 0.92 | KDM4E (0.44) | KDM4EPPARGPPARAFFAR1NPC1 | |
| SCHEMBL4038084 | 0.84 | FFAR1 (0.58) | KDM4EPPARGPPARAFFAR1PPARD | |
| SCHEMBL4035468 | 0.83 | KDR (0.57) | KDM4EPPARGPPARAFFAR1 | |
| SCHEMBL5201483 | 0.82 | KDM4E (0.63) | KDM4EPPARGPPARAFFAR1MAPT | |
| SCHEMBL4033261 | 0.81 | KDM4E (0.52) | KDM4EPPARGPPARAFFAR1PPARD | |
| SCHEMBL4029543 | 0.79 | PPARG (0.67) | PPARGPPARAFFAR1PPARD | |
| SCHEMBL4028344 | 0.79 | KDM4E (0.51) | KDM4EPPARGPPARAFFAR1PPARD | |
| SCHEMBL6998371 | 0.79 | KDM4E (0.53) | KDM4EPPARGPPARAFFAR1MAPT | |
| SCHEMBL4034810 | 0.77 | KDR (0.55) | PPARGPPARAFFAR1 | |
| SCHEMBL4035236 | 0.77 | PPARG (0.64) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1357115-B1 | ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2009-06-17 | — | — | EP | disclosed |
| US-7238716-B2 | Alkanoic acid derivatives process for their production and use thereof | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2007-07-03 | — | — | US | disclosed |
| US-20040058965-A1 | Alkanoic acid derivatives process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1357115-A1 | ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058965-A1 | Alkanoic acid derivatives process for their production and use thereof | GPR119, ACOX1, ALK | KDM4E 570/4885PPARG 593/4885PPARA 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.